Mature tertiary lymphoid structure associated CD103+CD8+Trm cells determined improved anti-tumor immune in breast cancer

被引:0
|
作者
Fang, Qin [1 ]
Chen, Shuru [1 ]
Chen, Xiaoyue [1 ]
Zou, Wei [1 ]
Chen, Di [1 ]
Huang, Yukang [1 ]
Wu, Chucheng [1 ]
机构
[1] Huizhou Cent Peoples Hosp, Huizhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2025年 / 15卷
关键词
breast cancer; tertiary lymphoid structures; CD103+CD8+Trm cells; prognosis factors; tumor immunology; B-CELLS; SURVIVAL;
D O I
10.3389/fonc.2025.1480461
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Although tertiary lymphoid structures (TLS) play crucial roles in the anti-tumor immune response and are associated with favorable prognoses in many solid tumors, the precise mechanisms by which TLSs enhance anti-tumor immunity remain poorly understood. The current study aimed to explore the relationship between the maturity of tertiary lymphoid structures and their key immune cells in combating breast cancer.Patients and methods In this study, we utilized immunofluorescence and H&E staining to detect tumor-resident memory T cells (Trm) and assess the maturity of TLS, analyzing their distribution and proportion in an annotated cohort of 95 breast cancer patients.Results The presence of tumor-associated TLSs was correlated with an improved prognosis in patients with breast cancer. The proportion of CD8+CD103+ resident memory T cells and natural killer (NK) cells within the TLSs was significantly higher than that in areas outside of these structures. Additionally, the proportions of CD103+ CD8+ Trm cells and NK cells were significantly increased with the gradual maturation of TLS. Furthermore, the secretion function of effector molecules by CD8+ CD103+ Trm cells and NK cells within TLSs was significantly enhanced, indicating a strong correlation between the effector function of CD103+ CD8+ Trm and NK cells and the maturity of TLSs.Conclusion Our study identifies potential additional prognostic information for the clinical prognosis of breast cancer patients, underscoring the prognostic significance of immune cells within TLS, with a particular focus on CD103+ CD8+ Trm cells and NK cells.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Foxp1 Regulates Anti-tumor Effector Functions of CD8+T cells in Ovarian Cancer
    Stephen, Tom
    Takata, Hiroshi
    Feng, Xiaoming
    Wang, Haikun
    Rutkowski, Melanie
    Allegrezza, Michael
    Hu, Hui
    Conejo-Garcia, Jose
    JOURNAL OF IMMUNOLOGY, 2012, 188
  • [32] CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
    Qadir, Abdul S.
    Guegan, Jean Philippe
    Ginestier, Christophe
    Chaibi, Assia
    Bessede, Alban
    Charafe-Jauffret, Emmanuelle
    Macario, Manon
    Lavoue, Vincent
    Rouge, Thibault de la Motte
    Law, Calvin
    Vilker, Jacob
    Wang, Hongbin
    Stroup, Emily
    Schipma, Matthew J.
    Bridgeman, Bryan
    Murmann, Andrea E.
    Ji, Zhe
    Legembre, Patrick
    Peter, Marcus E.
    ISCIENCE, 2021, 24 (11)
  • [33] CD103+tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+T cells associated with prognostic benefit and therapy response in cervical cancer
    Komdeur, Fenne L.
    Prins, Thalina M.
    van de Wall, Stephanie
    Plat, Annechien
    Wisman, G. Bea A.
    Hollema, Harry
    Daemen, Toos
    Church, David N.
    De Bruyn, Marco
    Nijman, Hans W.
    ONCOIMMUNOLOGY, 2017, 6 (09):
  • [34] MICROBIOTA-SPECIFIC T FOLLICULAR HELPER CELLS DRIVE TERTIARY LYMPHOID STRUCTURE FORMATION AND ANTI-TUMOR IMMUNITY IN COLORECTAL CANCER
    Overacre-Delgoffe, Abigail
    Bumgarner, Hannah
    Cillo, Anthony
    Burr, Ansen
    Tometich, Justin
    Bhattacharjee, Amrita
    Bruno, Tullia
    Vignali, Dario
    Hand, Timothy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A880 - A880
  • [35] Intratumoral B cells are essential for anti-tumor immune responses of tertiary lymphoid structures: Impact of STING and LTβR activation in pancreatic cancer
    Duah, Maxwell
    Kikuchi, Yasuhiro
    Stansel, Tomoko
    Csomos, Krisztian
    Hiraoka, Nobuyoshi
    Walter, Jolan
    Ware, Carl F.
    Komatsu, Masanobu
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [36] Bexarotene activates type 1 antigen presenting cells, increases tumor infiltrating CD8 T-cells, and augments the anti-tumor activity of chemotherapy in breast cancer
    Stanton, Sasha Elizabeth
    Gad, Ekram
    Corulli-Rastetter, Lauren R.
    Disis, Mary L.
    CANCER RESEARCH, 2017, 77
  • [37] CD4+ CD25+ FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer
    Clarke, Sarah L.
    Betts, Gareth J.
    Plant, Andrea
    Wright, Kate L.
    El-Shanawany, Tariq M.
    Harrop, Richard
    Torkington, Jared
    Rees, Brian I.
    Williams, Geraint T.
    Gallimore, Awen M.
    Godkin, Andrew J.
    PLOS ONE, 2006, 1 (02):
  • [38] IL-1R8 acts as an immune checkpoint in CD8+T cells, limiting cytokine-induced anti-tumor immune responses
    Supinol, Domenico
    Garuti, Roberto
    Mariancini, Andrea
    Perucchini, Chiara
    Carnevale, Silvia
    Ponzetta, Andrea
    Colombo, Federico Simone
    Magrini, Elena
    Rigatelli, Anna
    Minute, Luna Cordeiro
    Mapelli, Sarah
    Molgora, Martina
    Scavello, Francesco
    Di Ceglie, Irene
    Pezone, Giovanni
    Falcone, Laura
    Casucci, Monica
    Lugli, Enrico
    Jaillon, Sebastien
    Mantovani, Alberto
    Garlanda, Cecilia
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 344 - 344
  • [39] Dendritic cells present cancer-derived p:MHCl molecules to prime anti-tumor CD8 T cells
    MacNabb, Brendan
    Kline, Douglas
    Chen, Xiufen
    Tumuluru, Sravya
    Kline, Justin
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [40] Cancer stem-like cells evade CD8+CD103+ tumor-resident memory T (TRM) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model
    Corgnac, Stephanie
    Damei, Isabelle
    Gros, Gwendoline
    Caidi, Aziza
    Terry, Stephane
    Chouaib, Salem
    Deloger, Marc
    Mami-Chouaib, Fathia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)